Cue biopharma presents positive data update from ongoing phase 1 trials of cue-101 for recurrent/metastatic hpv+ head and neck squamous cell carcinoma at the 2023 american society of clinical oncology (asco) annual meeting

Boston, may 25, 2023 (globe newswire) --  cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, announced today the presentation of a positive data update from its ongoing phase 1 clinical trials evaluating its lead biologic from the il-2-based cue-100 series, cue-101, for the treatment of patients with human papilloma virus (hpv16+) recurrent/metastatic head and neck squamous cell carcinoma (r/m hnscc) as a monotherapy and in combination with pembrolizumab. the data will be presented in a poster by dr. christine chung, m.d., chair, department of head and neck-endocrine oncology, moffitt cancer center on june 5, 2023 at the asco annual meeting in chicago, il. in addition, the poster will also be highlighted by an expert head and neck cancer panel during a poster discussion session immediately following the scheduled poster presentation.
CUE Ratings Summary
CUE Quant Ranking